IL15 and neoplasm: Interestingly, the combination of high-affinity PD-L1-CAR NK cells withthe IL-15 superagonist and anti-PD-1 antibody has been already demonstrated by others to have superior tumor growth control of engrafted oral cavity squamous carcinoma tumors in mice.23 The effect of amplifying the PD-L1 expression can also serve as a stimulus for incorporating the PD-L1–CAR into combinations with other CAR-based strategies.